Understanding how SYNCRIP affects prostate cancer treatment resistance
Official title: Elucidating the Molecular Role of SYNCRIP in Prostate Cancer and AR Targeted Therapy Resistance
Funded at Yale University · NIH-11221969 · Data updated 2026-11-12
This study is looking at a protein called SYNCRIP to understand why some prostate cancers stop responding to hormone treatments, with the hope of finding new ways to help patients with advanced prostate cancer get better results from their therapies.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | May 1, 2021 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $467,016 |
| NIH project number | 7R37CA258730-05 |
| Project ID | NIH-11221969 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who are undergoing or have undergone androgen receptor targeted therapy.
✕Less likely to help
Patients with early-stage prostate cancer or those not receiving androgen receptor targeted therapies may not benefit from this research.
What this research studies
This research investigates the role of a protein called SYNCRIP in prostate cancer, particularly in cases where the cancer becomes resistant to hormone therapies. By studying how the loss of SYNCRIP is linked to treatment failure, the researchers aim to uncover the underlying mechanisms of resistance. They will use both laboratory experiments and patient samples to explore how SYNCRIP influences cancer cell behavior and response to therapy. The goal is to identify new therapeutic targets that could improve treatment outcomes for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for overcoming treatment resistance in prostate cancer, potentially improving survival rates for patients.
How similar studies have gone: Previous research has shown that targeting molecular mechanisms of therapy resistance can lead to significant advancements in cancer treatment, suggesting a promising avenue for this investigation.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Mu, Ping — Yale University
- Study coordinator: Mu, Ping
Related research
Other NIH-funded projects on the same topics.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
Understanding SYNCRIP’s role in prostate cancer resistance to AR-targeted therapy
A study at Yale is looking at how loss of SYNCRIP makes prostate cancer less responsive to common AR-targeted treatments and what this could mean for new ways to treat resistant cancer.
-
Genetic markers that predict treatment response in advanced prostate cancer
This project looks at whether tumor and inherited DNA changes can show which men with advanced prostate cancer are most likely to benefit from targeted drugs and immunotherapy.
-
How loss of SYNCRIP and APOBEC1 can drive resistance to prostate hormone therapy
Researchers are looking at how losing a protein called SYNCRIP and increased activity of the APOBEC1 enzyme may make advanced prostate cancer stop responding to common hormone-targeted treatments.
-
Measuring metabolic activity in prostate cancer bone metastases using advanced MRI techniques
This study is testing a new type of MRI that uses a special substance to see how well prostate cancer treatments are working in bone metastases, helping doctors spot early signs of success or resistance to therapy so they can better care for patients.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.